Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.42 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.42 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.42 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22301613 | 0.94 | KRAS (0.46) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL22301620 | 0.91 | KRAS (0.47) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646876 | 0.88 | KRAS (0.59) | KRAS | |
| SCHEMBL29765774 | 0.88 | KRAS (0.59) | KRAS | |
| SCHEMBL22301611 | 0.88 | KRAS (0.47) | KRAS | |
| SCHEMBL22301634 | 0.85 | KRAS (0.44) | KRAS | |
| SCHEMBL29765918 | 0.85 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17026486 | 0.85 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL22301643 | 0.83 | KRAS (0.48) | KRASCYP3A4CYP2D6CYP3A5CYP3A7 | |
| SCHEMBL22301622 | 0.82 | KRAS (0.44) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3630746-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110869357-A | Compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018218071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 97/4885HMOX2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.